Background: Fingolimod was the first oral disease-modifying treatment for relapsing-remitting multiple sclerosis. It has previously been associated with the development of lymphoma.
Objective: To describe a case of lymphomatoid papulosis, a CD30+ cutaneous lymphoproliferative disorder, in a patient taking fingolimod.
Methods: Case study.
Results: Our patient developed lymphomatoid papulosis 2 months after starting fingolimod. Histology confirmed the diagnosis. The drug was withdrawn. Resolution began only 2 days later.
Conclusions: Lymphomatoid papulosis is a benign subtype of cutaneous T-cell lymphoma, but up to 20% of cases can transform to a malignant course. Patients on fingolimod and physicians caring for them should be mindful of the need to monitor the skin.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/1352458515597568 | DOI Listing |
J Fr Ophtalmol
December 2024
Department of Ophthalmology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
J Dtsch Dermatol Ges
November 2024
Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
Bull Cancer
November 2024
Service de dermatologie et oncologie cutanée, centre hospitalier Estaing, CHU de Clermont-Ferrand, université Clermont-Auvergne, place Lucie-Aubrac, 63000 Clermont-Ferrand, France. Electronic address:
Kathmandu Univ Med J (KUMJ)
September 2024
Department of Dermatology and Venereology, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Maharajgunj, Kathmandu, Nepal.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!